Mexico approved the Oxford-AstraZeneca coronavirus vaccine for emergency use Monday, hoping to spur a halting vaccination effort that has only given about 44,000 shots since the third week of December, about 82 per cent of the doses the country has received.
Prior to this, the Pfizer vaccine was the only one approved for use in Mexico. Mexican regulators approved the AstraZeneca shot. Assistant Health Secretariat Hugo Lpez-Gatell said he erroneously reported approval for Chinese vaccine maker CanSino, noting it had not yet submitted full study results for safety and efficacy.
Mexico has pinned much of its hopes on the inexpensive, one-shot CanSino vaccine. It will makes things a lot easier for us, Lpez-Gatell said.
Lpez-Gatell, who heads up efforts to deal with the pandemic, had to explain why he was spotted at a Pacific coast beach, apparently sitting at sea-side restaurant without a face mask on.
Lpez-Gatell has repeatedly counselled Mexicans to stay at home. He has also cast doubt on how whether face masks protect people from catching coronavirus.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)